Our Story
What if you could simulate biology mathematically?
Cellarity was founded in 2017 at Flagship Pioneering's innovation foundry, Flagship Labs. Cellarity’s journey began with brainstorming sessions between Flagship Pioneering Founder and CEO Noubar Afeyan, Partner Avak Kahvejian and Principal Nick Plugis. The Flagship team recognized that powerful new biological and computational technologies exist to perturb and quantitate virtually any cellular or molecular component. They also envisioned that these technologies could generate the data necessary to unravel biological complexity. This strategy promises to produce drug candidates with improved fidelity through the discovery and development pipeline.
Thus, Cellarity was created – a first-of-its-kind therapeutics company discovering and developing medicines by studying and altering cell behaviors. With the unique ability to discover drugs based on cellular behavior, Cellarity’s goal is to increase the success rate and speed of drug discovery dramatically.
ABOUT FLAGSHIP
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $100 billion in aggregate value. To date, Flagship has deployed over $2.9 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies.